Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Kronos Bio, Inc. - Common Stock (NQ:KRON)

0.8800 UNCHANGED
Last Price Updated: 9:38 AM EDT, Jun 20, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Kronos Bio, Inc. - Common Stock

< Previous 1 2 3 4 Next >
Kronos Bio Highlights Data at AACR Ovarian Cancer Research Symposium that Supports Clinical Evaluation of Istisociclib in Advanced Ovarian Cancer
From Kronos Bio, Inc.
Via GlobeNewswire
Kronos Bio Announces Participation in Medical and Investor Conferences in September
From Kronos Bio, Inc.
Via GlobeNewswire
KRON Stock Earnings: Kronos Bio Beats EPS, Beats Revenue for Q2 2024
KRON stock results show that Kronos Bio beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024. 
Via InvestorPlace
Kronos Bio Reports Second Quarter 2024 Financial Results and Pipeline Update
From Kronos Bio, Inc.
Via GlobeNewswire
Recap: Kronos Bio Q4 Earnings
 
Via Benzinga
Kronos Bio Announces First Patient Dosed with KB-0742 in an Expansion Cohort Focused on Platinum-Resistant High-Grade Serous Ovarian Cancer
From Kronos Bio, Inc.
Via GlobeNewswire
12 Health Care Stocks Moving In Thursday's Intraday Session
 
Via Benzinga
Assertio Holdings And 2 Other Penny Stocks Insiders Are Buying
 
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Intraday Session
 
Via Benzinga
Why NetEase Shares Are Trading Lower? Here Are Other Stocks Moving In Friday's Mid-Day Session
 
Via Benzinga
Kronos Bio to Present Clinical Update on Phase 1/2 Trial of KB-0742 at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
From Kronos Bio, Inc.
Via GlobeNewswire
Kronos Bio to Participate in Three Upcoming Healthcare Conferences and Events
From Kronos Bio, Inc.
Via GlobeNewswire
Kronos Bio Appoints Deborah Knobelman, Ph.D. as Chief Operating Officer and Chief Financial Officer
From Kronos Bio, Inc.
Via GlobeNewswire
KRON Stock Earnings: Kronos Bio Misses EPS, Beats Revenue for Q1 2024
KRON stock results show that Kronos Bio missed analyst estimates for earnings per share but beat on revenue for the first quarter of 2024. 
Via InvestorPlace
Kronos Bio Reports First-Quarter 2024 Financial Results
From Kronos Bio, Inc.
Via GlobeNewswire
Kronos Bio to Present Clinical Update on Phase 1/2 Trial of KB-0742 at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
From Kronos Bio, Inc.
Via GlobeNewswire
KRON Stock Earnings: Kronos Bio Beats EPS, Beats Revenue for Q4 2023
KRON stock results show that Kronos Bio beat analyst estimates for earnings per share and beat on revenue for the fourth quarter of 2023. 
Via InvestorPlace
Kronos Bio Reports Recent Business Progress and Fourth-Quarter and Full-Year 2023 Financial Results
From Kronos Bio, Inc.
Via GlobeNewswire
Kronos Bio Announces Restructuring to Focus Resources on Clinical Development with Extended Cash Runway
From Kronos Bio, Inc.
Via GlobeNewswire
Kronos Bio To Present Three Posters at AACR 2024 Annual Meeting
From Kronos Bio, Inc.
Via GlobeNewswire
Kronos Bio Announces Participation in 44th Annual Cowen Health Care Conference
From Kronos Bio, Inc.
Via GlobeNewswire
Kronos Bio Implements New Leadership Structure to Drive Pipeline Advancement
Company eliminates three executive officer roles and appoints new Executive Leadership team 
From Kronos Bio, Inc.
Via GlobeNewswire
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
 
Via Benzinga
12 Health Care Stocks Moving In Thursday's Pre-Market Session
 
Via Benzinga
Cancer Player Kronos Bio To Stop Lanraplenib Combo Therapy Blood Cancer Study
Kronos Bio Inc (NASDAQ: KRON) says that after the review of data from the phase 1b portion of its phase 1b/2 trial of lanraplenib in combination with gilteritinib in FLT3-mutated relapsed/refractory... 
Via Benzinga
Uber To Rally Over 13%? Here Are 10 Top Analyst Forecasts For Tuesday
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. 
Via Benzinga
Kronos Bio Announces Pipeline Update and p300 KAT Inhibitor Development Candidate
From Kronos Bio, Inc.
Via GlobeNewswire
Kronos Bio Announces Participation in H.C. Wainwright 4th Annual Precision Oncology Virtual Conference
From Kronos Bio, Inc.
Via GlobeNewswire
Kronos Bio Announces Participation in 35th Annual Piper Sandler Healthcare Conference
From Kronos Bio, Inc.
Via GlobeNewswire
Why ReNew Energy Global Shares Are Trading Higher By Around 14%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Shares of ReNew Energy Global Plc (NASDAQ: RNW) gained during Monday’s session following strong quarterly sales. ReNew Energy Global posted quarterly sales of $345.00 million, topping market estimates... 
Via Benzinga
< Previous 1 2 3 4 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.